 The purpose of this trial is to evaluate efficacy and toxicity of either the combination of docetaxel, trastuzumab sc and pertuzumab arm A or trastuzumab emtansin arm B. Switch of therapy to the opposite treatment alternative is applicable in case of lack of response after two courses of treatment, or for medical reasons under exceptional circumstances drug reaction, other medical conditions at any point. After termination of the primary treatment follow-up for five years. 